Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Fig. 5

Safety evaluation of cisplatin combined with IL-2 versus cisplatin alone by thoracic injection for controlling MPE. a The incidence rate of chest pain in group of cisplatin combined with IL-2 was no difference with cisplatin alone (p > 0.05). b The incidence rate of the fever in group of cisplatin combined with IL-2 was higher than that in group of cisplatin alone (p = 0.001)

Back to article page